Behring - Human Hepatitis B and P Immunoglobulin
Hepatitis B Immunoglobulin-VF is a sterile, preservative-free solution containing 160 mg/mL human plasma protein of which at least 98% is immunoglobulin (mainly IgG), with a hepatitis B antibody titre of not less than 100 IU/mL. The pH value of the ready-to-use solution is 6.6. Hepatitis B Immunoglobulin-VF is manufactured from human plasma collected by Australian Red Cross Lifeblood. Hepatitis B Immunoglobulin-VF contains 22.5 mg/mL glycine.
The pH value of the ready-to-use solution is 6.6.
Hepatitis B Immunoglobulin-VF is manufactured from human plasma collected by Australian Red Cross Lifeblood.
Hepatitis B Immunoglobulin-VF contains 22.5 mg/mL glycine.
PHARMACEUTICAL FORM
Solution for intramuscular injection.
CLINICAL PARTICULARS
Therapeutic indications
Hepatitis B Immunoglobulin-VF is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis B antibody level is inadequate (
Post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to HBsAg-positive or suspected
HBsAg-positive material, for example, by needle stick, oral ingestion or sexual exposure.
Hepatitis B Immunoglobulin-VF is also indicated for prophylaxis in infants born to HBsAg-positive mothers.
Dosage
Prophylaxis with Hepatitis B Immunoglobulin-VF in adults following percutaneous or permucosal exposure to HBsAg-positive or suspectedHBsAg-positive material: Refer to Table 1.